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Introduction: Two recent, independent, studies conducted novel metabolomics analyses relevant to human sepsis
progression; one was a human model of endotoxin (lipopolysaccharide (LPS)) challenge (experimental endotoxemia)
and the other was community acquired pneumonia and sepsis outcome diagnostic study (CAPSOD). The purpose of
the present study was to assess the concordance of metabolic responses to LPS and community-acquired sepsis.
Methods: We tested the hypothesis that the patterns of metabolic response elicited by endotoxin would agree with
those in clinical sepsis. Alterations in the plasma metabolome of the subjects challenged with LPS were compared
with those of sepsis patients who had been stratified into two groups: sepsis patients with confirmed infection and
non-infected patients who exhibited systemic inflammatory response syndrome (SIRS) criteria. Common metabolites
between endotoxemia and both these groups were individually identified, together with their direction of change
and functional classifications.
Results: Response to endotoxemia at the metabolome level elicited characteristics that agree well with those observed
in sepsis patients despite the high degree of variability in the response of these patients. Moreover, some distinct features
of SIRS have been identified. Upon stratification of sepsis patients based on 28-day survival, the direction of change in 21
of 23 metabolites was the same in endotoxemia and sepsis survival groups.
Conclusions: The observed concordance in plasma metabolomes of LPS-treated subjects and sepsis survivors strengthens
the relevance of endotoxemia to clinical research as a physiological model of community-acquired sepsis, and gives
valuable insights into the metabolic changes that constitute a homeostatic response. Furthermore, recapitulation of
metabolic differences between sepsis non-survivors and survivors in LPS-treated subjects can enable further research
on the development and assessment of rational clinical therapies to prevent sepsis mortality. Compared with earlier
studies which focused exclusively on comparing transcriptional dynamics, the distinct metabolomic responses to systemic
inflammation with or without confirmed infection, suggest that the metabolome is much better at differentiating these
pathophysiologies. Finally, the metabolic changes in the recovering patients shift towards the LPS-induced response
pattern strengthening the notion that the metabolic, as well as transcriptional responses, characteristic to the
endotoxemia model represent necessary and “healthy” responses to infectious stimuli.* Correspondence: yannis@rci.rutgers.edu
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Sepsis is defined as the combination of an infection with
multiple features of ‘systemic inflammatory response
syndrome’ (SIRS) [1] and is one of the oldest and most
enigmatic conditions in medicine. There are more than
a million cases of sepsis per year in the United States [2]
and it is estimated that there are 19 million cases per
year worldwide [3,4]. According to the Centers for
Disease Control, the cost of hospitalization is in the
order of $15 billion, with an anticipated further increase
in the future [5]. Despite several decades of intensive
research and efforts to bring new therapies to the bedside,
the number of cases and sepsis-associated deaths are still
soaring [3,6]. Current treatment guidelines include
cardiorespiratory resuscitation and non-specific protocols
aimed at mitigating immediate threats of uncontrolled
infection [3]. A significant barrier to progress is the
perceived inadequacy of experimental models that can
reproduce the pathophysiology of the disease in humans.
The high degree of variability among patients and
multiple aspects of the disease, including patient gender,
age and comorbidities complicate the design of relevant
experimental models and clinical studies. Moreover, the
initiating cause of infection and the physiologic responses
that follow are also highly variable [7]. All these factors
explain, at least in part, the difficulty in translating experi-
mental results to the clinic and, consequently, the lack of
success in the development of effective therapies [8].
Endotoxemia, an experimental model in which healthy
volunteers are intravenously administered a form of
endotoxin (lipopolysaccharide, LPS, a major component
of Gram-negative bacteria outer membrane and a Toll-like
receptor 4 (TLR4) agonist) [9], has served as a valuable
experimental venue for more than six decades [10-12]. It is
a model of systemic inflammation, rather than a true
mimic of sepsis. Nonetheless, early transient physiochemical
changes and biochemical pathway activation in this model
are strikingly similar to those observed during the early
hyperdynamic phase of resuscitated injury and infection
[13]. The LPS challenge triggers chills, myalgias, nausea,
and an increase in core body temperature and heart rate,
most of which begin to abate within six to eight hours
[11,13,14]. Genome-wide analyses of circulating leukocytes
revealed transcriptional signatures indicative of changes in
protein translation and glycolysis [15], which shared similar
characteristics with those observed in trauma patients [16].
These studies helped elucidate the intricate regulatory
schemes governing the response to endotoxemia [16,17]
and provided the foundations for in silico models of
systemic inflammation [18-24]. More recently, we docu-
mented the effects of LPS-induced inflammation on the
whole body metabolism in humans [25]. In contrast with
other methods applied to the endotoxemia model,
metabolomics reflects the combined output of all tissuesin the body [26]. In that study [25], plasma samples,
collected from healthy subjects during 24-hours post
challenge with LPS, were subjected to non-targeted
biochemical profiling, revealing the temporal changes
in the plasma metabolome. Unsupervised multivariate
analyses identified prominent changes in lipid and
protein metabolism, which peaked at six hours post
LPS infusion. Subsequently, to understand better how
the inflammatory responses at the level of cells and
whole body correlate in humans, we integrated the
analysis of the plasma metabolome with that of the
leukocyte transcriptome [27].
In [28], an integrated analysis of clinical features,
plasma metabolome and proteome described the pattern
of metabolic perturbations in critically ill patients
presenting with symptoms of SIRS or sepsis. This
study, the first of its kind, examined clinical features
as well as the plasma metabolome, and proteome, of
patients upon arrival at the emergency department (ED)
and 24 hours later. An important and novel outcome of
the study was the realization that metabolic differences
could ultimately be used as markers predicting survival.
Since the endotoxemia model utilizes LPS, rather than
intact bacteria, there is an ongoing concern that data
derived from this model are of limited relevance to
our understanding of sepsis-induced inflammatory
mechanisms, although recent analyses of the leukocyte
transcriptome seemed to argue otherwise [15]. The avail-
ability of new metabolomic data [25,28] offered the oppor-
tunity to compare responses detected in LPS-challenged
subjects to those of critically ill patients at the level of the
entire organism. In this retrospective study we aimed to
objectively determine the relevance of the information
content gained by parallel analyses of LPS-challenged
subjects [25] and patients with or without community-
acquired sepsis [28]. Our study identified a core response
that was in agreement with what was observed in sepsis
patients. Response to systemic inflammation without
apparent infectious stimuli such as what is observed in
SIRS was shown to have distinct features that may make it
uniquely recognizable at the metabolomics level.
Metabolic changes in the patients who are recovering
shifted towards an endotoxemia response pattern,
strengthening the idea that the endotoxemia model repre-




This is a retrospective analysis utilizing metabolomes
obtained from subjects who participated in an experimen-
tal endotoxemia study and from patients with or with-
out community-acquired sepsis. In brief, as previously
described [25], healthy volunteers participated in an
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consent under guidelines approved by the Institutional
Review Board of Rutgers - Robert Wood Johnson Medical
School. Inclusion criteria were age between 18 to 40 years,
and normal general health as demonstrated by medical
history and physical examination as well as laboratory
testing. National Institutes of Health (NIH) Clinical
Center Reference Endotoxin at a bolus dose of 2 ng/kg
body weight was administered to 15 subjects. Blood
samples were collected at t = 0, prior to treatment, and at
1, 2, 6, and 24 hours post-treatment (Figure 1, top). Mass
spectrometry (MS) based biochemical analysis of the
plasma samples was performed by Metabolon (Durham,
NC, USA) according to previously published methods
[29]. All details of the study design and biochemical
analysis are available in [25].
Metabolomic data for the clinical cases of systemic
inflammation were obtained from the Community
Acquired Pneumonia and Sepsis Outcome and Diagnostics
(CAPSOD) study [28]. Approval for this study was
obtained by institutional ethics committees and details were
filed at ClinicalTrials.gov (NCT00258869). Protocols and
identified clinical features in the different classes of patients
were previously published. The study [28] included 1,152
individuals with suspected, community-acquired sepsis
(acute infection and ≥2 SIRS criteria) in the emergency
departments at three urban, tertiary-care hospitals in the
United States between 2005 and 2009. Each patient or their
legal designates provided informed consent. Medical
history, physical examination, and acute illness scores
(Acute Physiology and Chronic Health Evaluation IIFigure 1 Schematic description of the experimental and clinical sourc(APACHE II) and Sequential Organ Failure Assessment
(SOFA)) were recorded at enrollment (t0,clinical) and
24 hours later (t24,clinical). Infection status and outcome
through day 28 were independently determined by
board-certified clinicians. Clinical care given for the
patients was not standardized and was determined by
individual providers. After independent audit of infection
status and outcomes, 150 patients were chosen for deriv-
ation studies. Non-targeted mass spectrometry based
analyses of the patients’ blood samples were done by
Metabolon similarly to the endotoxemia study.
The 150 patients chosen for derivation studies within
the CAPSOD cohort were classified to represent cases of
uncomplicated sepsis (n = 27), severe sepsis (n = 25),
septic shock (n = 38), non-infected SIRS (‘ill’ controls,
indicated as SIRS, presumed septic at enrollment but
later determined to have noninfectious reasons for
SIRS; n = 29) or sepsis non-survival (SNS, n = 31)
(Figure 1, bottom). No significant differences among
subgroups of sepsis survivors (uncomplicated sepsis,
severe sepsis, septic shock) were reported for plasma
metabolites [28]. Therefore, the data from these patients
were collapsed into a single group referred to as sepsis
survivors (SS, n = 90) for the purposes of this study.
Furthermore, in the first part of the analysis, metabolic
data from SS and sepsis non-survivors (SNS) were pooled
to assess the similarities and differences between sepsis
and non-infected SIRS, and referred to as the Sepsis group
(n = 121). In the subsequent analysis, data from the SS
and SNS groups were used individually to investigate the
association of metabolic changes in endotoxemia withes of data used.
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patients.Data analysis
MS analysis of plasma samples from the human endo-
toxemia study provided temporal information on 366
metabolites at five time points. Previous results of the
principal component analysis on this dataset showed
that the six hour time point (t6) was the most critical
since the maximum difference between control and
treatment groups was observed at this time point [25]. This
agreed well with prior transcriptional studies indicating
that the maximal change in leukocyte gene expression was
observed six hours after the LPS administration [16,30].
Therefore, this data point was considered to represent the
peak of metabolic response to endotoxemia and used as
reference for the assessment of concordance between
experimental and clinical data in this study. MS analysis of
the samples from the CAPSOD study, on the other hand,
had identified 370 metabolites at t0,clinical (time of hospital
admission) and 401 metabolites at t24,clinical (24 hours after
admission). In this study, both clinical and experimental
datasets were individually normalized by setting the
median equal to 1. Missing values were imputed with the
observed minimums after normalization. The metabolite
lists were consolidated. Only the metabolites commonly
identified in the endotoxemia [25] and clinical [28] studies
were analyzed further. The final dataset included 177
common metabolites from both studies [25,28]. Outliers
were removed using the median absolute deviation,
MAD= 1.4826 × |(xi –Medianj(xj)|, of each metabolite, de-
termined in each individual group [31,32]. Subsequently, the
score for each data point was calculated zi ¼ xi−Medianj xjð Þj jMAD
and data points with a score above 3 were removed from
the dataset. The number of removed outliers for each group
is reported in Additional file 1: Table S1.
The baseline of the human endotoxemia studies, that
is, samples collected before LPS administration (t0,LPS),
defined the ‘baseline’ in this study. We identified the six
hour time point as the peak of the metabolic response in
the endotoxemia model in our previous metabolomics
study [25], as well as transcriptomic analysis [17,18], and
hypothesized that this time point represents the point of
transition from the development and recovery phases of
the response. For the clinical data collection, the starting
point was the time of hospital admission (t0,clinical),
whereas the second clinical time point was 24 hours
later (t24,clinical). Since the data obtained for the clinical
patients lack internal controls, for obvious reasons,
the responses of each group of patients, as well as
the endotoxemia subjects, were compared independently
to the healthy baseline (t0,LPS). For comparing the means
of metabolites in each condition relative to the healthybaseline, Welch’s t-test was used without assuming equal
variances (α = 0.05). The number of subjects in the experi-
mental endotoxemia group (n = 15) was much smaller than
the number of patients in the clinical groups to assume
normal distribution required for the t-test. However, at both
t0,LPS and t6,LPS, the data passed the Kolmogorov-Smirnov
test for each metabolite allowing the application of the
t-test. Q-values were calculated according to the
Benjamini and Hochberg procedure [33] and metabolites
having a P- and a q-value less than 0.05 are called signifi-
cant. We also evaluated how dispersed the data for each
metabolite is in clinical cases with respect to those at the
baseline. Variances of the significant metabolites in each
condition were also plotted relative to the variances at the
baseline and are shown in Additional file 2: Figure S1. The
direction and magnitude of changes in plasma metabolite
concentrations were determined based on log2 fold changes
from t0,LPS for both clinical groups and plotted against
those observed for endotoxemia as shown in Figure 2. The
full list of the metabolites, their significance in each condi-
tion, the direction and magnitude of the changes relative to
the baseline is provided in Additional file 3: Table S2.
We lastly focused on changes in metabolites within
subpopulations of sepsis patients who ultimately survived,
and those who did not. For this purpose, dynamics within
the sepsis group were examined using the data from the
SS and SNS groups. Metabolites that statistically differed
between these groups at either time point were determined
by t-test as described earlier. The magnitude of changes in
plasma metabolites relative to t0,LPS were calculated for
each group. These changes were compared between
the SS and SNS groups at both time points and with
the endotoxemia group at t6,LPS.
Results and discussion
Endotoxemia induced by elective administration of LPS
to healthy subjects has served as an invaluable tool
for obtaining mechanistic insight into homeostatic
inflammatory responses. Previous studies compared
transcript- and protein-expression patterns in immune
cells obtained from LPS treated subjects and trauma
patients, revealing significant overlap [15,34]. More re-
cently, metabolomics analyses in both LPS-administered
subjects [25] and patients with symptoms of systemic
inflammation at time of presentation to emergency
departments were published [28,35]. Building on these
prior studies [26,29], here we aimed to objectively com-
pare metabolic indices obtained from experimental studies
and clinical sources.
The inherent dynamics of a clinical and an experimental
study are obviously disparate although they focus on related
physiologic phenomena. The first time point in a clinical
study is generally at a point that had already deviated from
what can be called a ‘healthy state,’ whereas experimental
Figure 2 Scatter plots show the direction and extent of changes in the metabolites that significantly deviated from baseline in sepsis
(A) and SIRS (B) groups in relation to corresponding trends in endotoxemia. For the clinical data, plots reflect the maximum observed
change from the baseline if that particular metabolite was found to be significant in both time points, t0,clinical and t24,clinical. SIRS, severe
inflammatory response syndrome.
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under controlled conditions. In this study, we aimed
to evaluate the significance of observed metabolic
perturbations in endotoxemia and how they relate to
corresponding changes observed in patients with
symptoms of community-acquired sepsis at the time
of presentation to the emergency departments. In line
with our objective, we chose to evaluate each condition
and each time point based on its deviation from one com-
mon baseline that reflects a healthy state (t0,LPS). Table 1
shows the number of metabolites that had a significantly
different concentration compared to t0,LPS at each time
point available for each condition. The first column in
Table 1, shows the total information content of the finalTable 1 Number of significantly changed metabolites and me
for LPS-challenged subjects and patient groups
LPS (number = 15)
Super pathway Total t6
Amino acid 55 28
Carbohydrate 16 4







Significance was determined by comparing responses of each group of patients, as we
t-test was used and with correction for multiple comparisons by the Benjamini and Ho
0.05 are called significant. (The complete list is available in Additional file 3: Table S2).consolidated dataset with total number of metabolites
associated with each metabolic super-pathway. The
complete list of metabolites, their pathway classification,
and extent of changes from baseline are provided in
Additional file 3: Table S2. At the peak of the
response to LPS, that is, at t6,LPS, there were 83 metabo-
lites (47% of the total 177 common metabolites) which
significantly deviated from baseline. In contrast, the num-
ber of metabolites that significantly differed from baseline
for the clinical groups was considerably smaller (varying
between 19 to 26 metabolites, or 11% to 15% of the total
177 common metabolites). We hypothesize that the much
larger number of metabolites that changed significantly in
response to endotoxin as compared to the clinical casestabolic super-pathways that they belong to, determined
Sepsis (number = 121) SIRS (number = 29)
t0 t24 t0 t24
3 5 3 4
1 2 2 2
2 1 2 1
10 16 12 16
0 1 1 1
0 0 1 0
0 0 0 0
3 1 0 1
19 26 21 25
ll as endotoxemia subjects, to the healthy baseline (t0,LPS) individually. Welch’s
chberg procedure. (α = 0.05). Metabolites having a P- and a q-value less than
LPS, lipopolysaccharide; SIRS, severe inflammatory response syndrome.
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between physiologic variability of responses elicited in
subjects who participated in the controlled endotoxemia
study and patients. The endotoxemia study cohort
included relatively young and healthy subjects whereas the
patient cohort that participated in the CAPSOD study was
variable, in terms of age and comorbidities among others.
In addition, the trigger itself, that is, LPS, activates a single
TLR4-dependent signaling pathway, whereas infectious
agents and trauma activate multiple ones, leading to
greater variability in responses. In order to evaluate the
level of dispersion in the clinical data with respect to the
experimental, the variance of each significant metabolite
at each clinical condition was calculated and plotted
against the corresponding variance at the baseline.
These plots are show in Additional file 2: Figure S1.
As highlighted in these plots, variances of the metabolites
measured in the patients were statistically higher than
those measured in the endotoxemia study participants at
the baseline, t0,LPS, reflecting the fundamental differences
in variability between the two groups.
Next, we sought to determine the similarities and
differences among the subsets of significant metabolites
that changed significantly in the sepsis and SIRS groups
which were also significant in endotoxemia. Our intention
was to be maximally inclusive of the clinically observed
changes. Therefore, we focused on metabolites that were
significantly different from the baseline at either one of
the two clinical time points as well as in endotoxemia.
Table 2A lists the metabolites common to endotoxemia
and sepsis and Table 2B lists those common to endotoxemia
and SIRS. Metabolites that are common to both lists A and
B are typed in bold. Triangles depict the direction (apex up:
increase, apex down: decrease) and magnitude (one triangle:
less than two fold change, two triangles: more than two fold
change) of the difference relative to the baseline (t0,LPS).
Although the total number of metabolites in common with
endotoxemia is close for the two clinical cases (16 in
Table 2A and 18 in Table 2B), the agreement between the
directions of change is strikingly different. Bilirubin,
docosapentaenoate (DPA) and palmitolate were the
only three metabolites common to the LPS, sepsis and
SIRS groups, which changed in the same direction. Of the
16 metabolites common to LPS and sepsis (Table 2A), 15
changed in the same direction. Only one, xylose, changed
in an opposite direction. In marked contrast, of the total
18 metabolites common to the endotoxemia and SIRS
groups, 10 changed in the opposite direction (Table 2B).
Scatter plots shown in Figure 2A and B highlight this
distinction in response. The axes of the scatter plots indi-
cate the log2 fold changes in metabolite concentrations.
The x-axes show the change at t6,LPS from baseline, t0,LPS.
The y-axes show the maximum change in the clinical data
at either t0,clinical or t24,clinical, relative to t0,LPS (if thechanges at both time points were significant, the higher of
the two values is shown). Positive direction shows an
increase in concentration, while negative shows a decrease.
Accordingly, the concentrations of metabolites in the first
and third quadrants change in parallel with the observa-
tions in endotoxemia; while the ones in the second and
fourth quadrants change in the opposite direction. The
response reflected by the direction and magnitude of
change in septic patients agrees well with response to LPS
within this common subset. However, for the SIRS group,
the directions of change are not in agreement with those in
endotoxemia for more than half of the metabolites. This
suggests that, at the whole body metabolome level, SIRS
elicits a unique response with distinctive features. One such
feature is the marked decrease in sulfated androgenic
hormones (epiandrosterone sulfate, androsterone sul-
fate, dehydroisoandrosterone sulfate (DHEA-S), 5alpha-
pregnan-3beta,20alpha-diol disulfate) (Additional file 3:
Table S2). Lower plasma concentration of one of these
metabolites, DHEA-S, has previously been associated with
other systemic inflammatory diseases, such as systemic
lupus erythematosus and inflammatory bowel disease [36].
This supports the idea that the inflammatory response
without apparent infectious stimuli might elicit distinctive
features not shared with sepsis or endotoxemia. It has
been previously suggested that acute inflammatory
stresses from different etiologies result in highly similar
responses in humans at the genomic level [37]. The
observed distinct metabolomic responses to systemic
inflammation with or without confirmed infection,
however, suggest that the metabolome is much better
at differentiating and understanding the various path-
ophysiologies of the different systemic inflammatory
responses. Identified unique features of the inflammatory
response in different contexts may aid in improving the
diagnosis or the development of more targeted therapies.
Next we compared the trends of changes in metabolites
within subgroups of clinical patients who ultimately
survived (SS) or did not survive (SNS), and how they
related with those in endotoxemia. In total, there were 78
differential metabolites between SS and SNS groups at
either t0 or t24. Among these, 23 were also differential for
the endotoxemia group at t6. The direction and magnitude
of changes in these 23 metabolites are shown in Table 3.
When comparing the number of differential metabolites
at either t0 and t24 of the SS and SNS groups, it is clear
that the difference in metabolites becomes substantially
more pronounced with time. Alignment of trends in the
SS and SNS groups at t24 with those in endotoxemia at t6
revealed that the peak response to LPS is in line with the
sepsis survivor metabolic response, especially at the first
day into their treatment. In our previous metabolomics
study [25], we identified the six hour time point as the
peak of metabolic response in the endotoxemia model,
Table 2 Metabolites which are significantly different than the heathy baseline (t0,LPS) in the experimental condition
and either of the two time points in the clinical conditions
A LPS Sepsis
Metabolite name Super pathway t6 t0 t24
2-hydroxybutyrate (AHB) Amino acid ▲ = ▲
mannose Carbohydrate ▲ = ▲
xylose Carbohydrate ▲ = ▽
hexanoylcarnitine (C6) Lipid ▲ ▲ ▲
bilirubin Cofactors and vitamins ▲▲ ▲ ▲▲
docosapentaenoate (DPA; 22:5n3) Lipid ▲▲ = ▲
palmitoleate (16:1n7) Lipid ▲▲ ▲ ▲
pregnen-diol disulfate Lipid ▲▲ ▲ ▲
citrulline Amino acid ▽ ▽ ▽
histidine Amino acid ▽ = ▽
serine Amino acid ▽ = ▽
threonine Amino acid ▽ ▽ =
2-palmitoyl-GPC (16:0) Lipid ▽ ▽ ▽
uridine Nucleotide ▽ = ▽
gamma-glutamyltyrosine Peptide ▽ = ▽
catechol sulfate Xenobiotics ▽▽ ▽ =
B LPS SIRS
Metabolite name Super pathway t6 t0 t24
alpha-ketobutyrate Amino acid ▲ = ▽
N-acetylglycine Amino acid ▲ = ▽
xylose Carbohydrate ▲ = ▽
citrate Energy ▲ ▲ ▲
arachidonate (20:4n6) Lipid ▲ ▲ ▲
docosahexaenoate (DHA; 22:6n3) Lipid ▲ ▲ =
eicosapentaenoate (EPA; 20:5n3) Lipid ▲ = ▲
octadecanedioate (C18) Lipid ▲ = ▽
bilirubin Cofactors and vitamins ▲▲ ▲ =
3-hydroxybutyrate (BHBA) Lipid ▲▲ = ▽▽
docosapentaenoate (DPA; 22:5n3) Lipid ▲▲ ▲ =
hexadecanedioate (C16) Lipid ▲▲ ▽▽ ▽
palmitoleate (16:1n7) Lipid ▲▲ ▲ ▲
5-oxoproline Amino acid ▽ ▽ =
proline Amino acid ▽ = ▲
serine Amino acid ▽ ▲ =
1-linoleoyl-GPC (18:2) Lipid ▽ ▲ ▲
1-oleoyl-GPC (18:1) Lipid ▽ = ▲
A lists the metabolites common for endotoxemia and sepsis; B lists those common for endotoxemia and SIRS. (=: no significant difference from t0,LPS. ▲/▽: less
than two fold difference from t0,LPS; ▲▲/▽▽: more than two fold difference from t0,LPS; metabolite name in bold: common to both lists A and B). LPS,
lipopolysaccharide; SIRS, severe inflammatory response syndrome.
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tion from the development and recovery phases of the re-
sponse. The fact that the metabolic changes in the
recovering patients shift towards this response patternstrengthens the notion that the metabolic, as well as tran-
scriptional responses, characteristic to the endotoxemia
model represent necessary and ‘healthy’ responses to an
infectious stimuli. This is further evidence of likely
Table 3 The subset of metabolites having significantly different concentrations between SS and SNS groups at either
clinical time points
Sepsis survivors (number = 90) Sepsis non-survivors (number = 31) LPS (number = 15)
Metabolite name Super pathway t0 t24 t0 t24 t6
2-hydroxybutyrate (AHB) Amino acid ▲ - ▲ - ▲
N-acetylglycine Amino acid ▽ ▽ ▲ ▽ ▲
xylose Carbohydrate - ▽ - ▲ ▲
malate Energy - ▲ - ▲ ▲
10-nonadecenoate (19:1n9) Lipid - ▲ - ▲ ▲
2-hydroxypalmitate Lipid ▲ - ▲ - ▲
hexanoylcarnitine (C6) Lipid ▲ ▲ ▲▲ ▲▲ ▲
pregn steroid monosulfate Lipid ▲ - ▽ - ▲
3-hydroxybutyrate (BHBA) Lipid - ▲ - ▲▲ ▲▲
2-methylbutyroylcarnitine (C5) Amino acid ▽ ▽ ▲ ▲ ▽
3-indoxyl sulfate Amino acid - ▽ - ▲ ▽
5-oxoproline Amino acid - ▽ - ▲ ▽
histidine Amino acid - ▽ - ▽ ▽
isobutyrylcarnitine (C4) Am ino acid - ▽ - ▲ ▽
N-acetylornithine Amino acid - ▽ - ▽▽ ▽
tryptophan Amino acid - ▽ - ▽ ▽
threitol Carbohydrate - ▽ - ▲ ▽
phosphate Energy ▽ ▽ ▲ ▲ ▽
1-linoleoyl-GPC (18:2) Lipid - ▽ - ▽ ▽
1-oleoyl-GPC (18:1) Lipid - ▽ - ▽ ▽
2-palmitoyl-GPC (16:0) Lipid ▽ ▽ ▽▽ ▽▽ ▽
propionylcarnitine (C3) Lipid ▲ ▽ ▲ ▲ ▽
allantoin Nucleotide ▽ ▽ ▲ ▲ ▽
Changes from the healthy baseline, t0,LPS: ▲/▽: less than two fold change; ▲▲/▽▽: more than two fold change, −: there was not a significant difference
between SS or SNS groups). LPS, lipopolysaccharide; SNS, sepsis non-survivors; SS, sepsis survivors.
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at the appropriate level of distress required for graceful
resolution parallel to the one developed in the LPS model,
versus the systemic maladaptation observed in non-
survivors [28]. Based on this rationale, the endotoxemia
model could be classified as a model of ‘normal, healthy
responses.’ It is interesting to note that Matzinger [38]
more than a decade ago proposed that the Toll-like
receptors, including TLR4, evolved to serve as host
defense mechanisms against major injury and trauma.
Matzinger also proposed that the bacteria evolved to
use this receptor system to its own advantage. This
idea begins to explain why, when sufficiently controlled,
LPS-induced responses might be protective and necessary
rather than harmful.
The major goal of the CAPSOD study was to identify
metabolite changes at sepsis presentation that predicted
survival or death. Upon stratification of sepsis patients
based on 28-day survival, the direction of change of 21
of 23 metabolites was the same in endotoxemia and sepsissurvival (Table 3). The most important metabolite group
that differentiated surviving and non-surviving CAPSOD
patients was acyl-carnitines [28]. In our analysis, we
observed a similar trend with all significantly chan-
ged acyl-carnitines exclusively higher than the t0,LPS
baseline at both time points in sepsis non-survivors
(Additional file 4: Table S3), whereas for the surviving
patients, around half of the acyl-carnitines were below the
baseline. For the endotoxemia group, the direction of
change in acyl-carnitine concentrations at t6,LPS was
the same as that of sepsis survivors (4 of total 12
acyl-carnitines were significant at t6,LPS).
Finally, a number of confounding factors need to be
acknowledged. Firstly, the timing of the data collection,
and, therefore, the phase of the response that is being stud-
ied, can vary greatly depending on the lag time from the
initiating event to the presentation to an emergency depart-
ment. Secondly, the nutritional input, being non-controlled
either before or after the hospital admission, could
have affected the plasma metabolite concentrations as
Kamisoglu et al. Critical Care  (2015) 19:71 Page 9 of 10an independent factor. Thirdly, some of the CAPSOD
patients either had prior comorbidities that were likely to
affect the metabolome, such as diabetes mellitus, or were
also developing conditions which further exacerbated the
response, including compromised renal function, a likely
major contributor to the observed metabolome.
Conclusions
Therapeutic strategies that are successfully translated
into the clinic are very few and mostly non-specific in the
field of critical care. This is due, in part, to the complex and
dynamic physiological processes involved. Heterogeneity of
the patient populations and consequent challenges in
performing insightful clinical studies also have contributed
to the lack of progress in this realm of medicine [3,39].
Emerging -omics tools that are capable of examining
physiologic responses at the systems level are promising,
especially for complex conditions, such as sepsis and SIRS
[40]. The major caveat related to these tools is that since
the biological processes are analyzed at a higher level,
inter-species differences become as relevant to the response
as the sought-after question itself. Therefore, utility of the
animal models has been questioned recently in the
scientific community [37,41].
The human endotoxemia model has been serving as a
useful experimental platform for gaining insight into the
mechanisms governing systemic inflammation. It is a
recognized fact that this model does not fully replicate
the magnitude of physiologic stress created by trauma or
infection [13,14]; however, it gives researchers the
opportunity to study the mechanisms underlying the
response to systemic inflammation and relevant therapy
options without the inter-species differences obscuring
the interpretation of the results.
Progression of response to systemic inflammation in-
duced by endotoxemia in immune cells has been described
at the genomic level [16,30]. Moreover, comparison of the
response to experimental stimuli and traumatic/infectious
insults revealed significant overlap of common features
both at the gene [15] and protein expression levels [34]. In
the light of these observations, the current study aimed at
an objective evaluation of the concordance between experi-
mental and clinical cases of systemic inflammation and
benchmarked endotoxemia against sepsis of various origins
at the level of metabolic response. The plasma metabolome
can be thought of as the metabolic fingerprint representa-
tive of the state of the body at any given time and provide
information on the dominant regulatory mechanisms at
various levels of cellular processes including transcription,
translation and signal transduction. For effective provision
of critical care, understanding the alterations in the
plasma metabolome is crucial, because metabolite
levels impact the regulation of anti-inflammatory defenses,
in turn, through steering critical cellular processes andimmune mechanisms. Therefore, we think that the assess-
ment of the relevance of endotoxemia as an experimental
model representing critical illness is important.
We believe that the observed concordance between the
responses of LPS-treated subjects and sepsis patients at the
metabolome level, despite observed variability in clinical
data, strengthens the relevance of endotoxemia to clinical
research as an elementary tool and gives valuable
insights into the metabolic changes necessary for proper
response to inflammatory stress at the systemic level.Key messages
 We compared the metabolic response at the peak of
LPS-induced acute inflammation with those from
sepsis patients
 For the metabolites shown to change significantly
from the baseline, the direction and magnitude of
the changes were in agreement with what was
observed in sepsis patients.
 The metabolic response in SIRS patients was shown
be distinct from those in endotoxemia or sepsis.
 Metabolic changes in the surviving sepsis patients
shifted towards those observed in endotoxemia as
their recovery proceeded.
 These observations strengthened the relevance of
endotoxemia to clinical research as a valuable
experimental tool which can enable further research
on the development and assessment of rational
clinical therapies to prevent sepsis mortality.Additional files
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